Detection of circulating tumor cell-specific markers in breast cancer patients using the quantitative RT-PCR assay.

PubWeight™: 0.79‹?›

🔗 View Article (PMID 25708591)

Published in Int J Clin Oncol on February 24, 2015

Authors

Hye-Young Wang1, Sungwoo Ahn2, Sunghyun Kim2,3, Sunyoung Park2, Dongju Jung4, Sangjung Park5, Hyunju Han6, JooHyuk Sohn7, SeungIl Kim8, Hyeyoung Lee9

Author Affiliations

1: M&D, Inc., Wonju Eco Environmental Technology Center, Wonju, Gangwon, Republic of Korea.
2: Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University, 1 Yonseidae-gil, Wonju, Gangwon, 220-710, Republic of Korea.
3: Institute for Life Science and Biotechnology, Yonsei University, Seoul, Republic of Korea.
4: Department of Biomedical Laboratory Science, College of Natural Sciences, Hoseo University, Chungnam, Republic of Korea.
5: Department of Clinical Laboratory Science, College of Medical Science, Daegu Haany University, Daegu, Republic of Korea.
6: Avison Biomedical Research Center, Yonsei University Medical Center, Seoul, Republic of Korea.
7: Division of Medical Oncology, Severance Breast Cancer Clinic, Yonsei Cancer Center, Seoul, Republic of Korea.
8: Department of Surgery, Yonsei University College of Medicine, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, Republic of Korea. skim@yuhs.ac.
9: Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University, 1 Yonseidae-gil, Wonju, Gangwon, 220-710, Republic of Korea. hyelee@yonsei.ac.kr.

Articles cited by this

Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res (2007) 6.59

Breast cancer as a global health concern. Cancer Epidemiol (2009) 2.71

HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res Treat (2010) 2.12

Circulating tumour cells in clinical practice: Methods of detection and possible characterization. Methods (2010) 1.81

Circulating tumour cell detection: a direct comparison between the CellSearch System, the AdnaTest and CK-19/mammaglobin RT-PCR in patients with metastatic breast cancer. Br J Cancer (2009) 1.55

Detecting circulating tumor cells: current challenges and new trends. Theranostics (2013) 1.55

Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ system. Int J Cancer (2011) 1.38

KI-67 AND hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma. Mod Pathol (2003) 1.36

Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST. J Cancer (2010) 1.27

Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study. Breast Cancer Res (2012) 1.21

Estrogen and progesterone hormone receptor status in breast carcinoma: comparison of immunocytochemistry and immunohistochemistry. Indian J Cancer (2010) 1.15

Circulating tumor cells in breast cancer. Curr Opin Obstet Gynecol (2008) 1.06

Efficiency of whole genome amplification of single circulating tumor cells enriched by CellSearch and sorted by FACS. Genome Med (2013) 1.05

Vimentin expression appears to be associated with poor prognosis in node-negative ductal NOS breast carcinomas. Am J Pathol (1990) 1.03

Micrometastatic disease in breast cancer: clinical implications. Eur J Cancer (2008) 1.03

Circulating tumor cells in solid tumor in metastatic and localized stages. Anticancer Res (2009) 1.00

The clinical significance of disseminated tumor cells in breast cancer. Nat Clin Pract Oncol (2007) 0.97

Outcomes in young women with breast cancer of triple-negative phenotype: the prognostic significance of CK19 expression. Int J Radiat Oncol Biol Phys (2007) 0.96

Clinical utility of circulating tumor cell counting through CellSearch(®): the dilemma of a concept suspended in Limbo. Onco Targets Ther (2014) 0.86

Circulating and disseminated tumor cells in the clinical management of breast cancer patients: unanswered questions. Oncology (2009) 0.85

HER-2 DNA quantification of paraffin-embedded breast carcinomas with LightCycler real-time PCR in comparison to immunohistochemistry and chromogenic in situ hybridization. Clin Biochem (2006) 0.80

Detection of circulating tumor cells in patients with breast cancer using the quantitative RT-PCR assay for monitoring of therapy efficacy. Exp Mol Pathol (2014) 0.79

TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer. Future Oncol (2013) 0.75